Market Place
Sourcing Support
Prometheus team returns with brand-new biotech and $400M
21 Mar 2024 //
FIERCE BIOTECH
Merck closes $10.8B deal with Prometheus
17 Jun 2023 //
ENDPTS
Prometheus Biosciences Investor Alert By Former Attorney General Of Louisiana
22 May 2023 //
BUSINESSWIRE
Prometheus Biosciences Reports1Q 2023 FYR & Highlights Recent Corporate Progress
09 May 2023 //
GLOBENEWSWIRE
Merck battled 2 other Big Pharmas in pursuit of Prometheus
02 May 2023 //
FIERCE BIOTECH
Prometheus reportedly drew a competing AbbVie bid, initial partner interest
01 May 2023 //
ENDPTS
Merck Strengthens Pipeline with Acquisition of Prometheus Biosciences, Inc.
16 Apr 2023 //
PRESS RELEASE
Prometheus to Present at the Oppenheimer 33rd Annual Healthcare Conference
09 Mar 2023 //
GLOBENEWSWIRE
Prometheus Reports Fourth Quarter and Full-Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Prometheus Biosciences Announces Two Oral Presentations on PRA023
22 Feb 2023 //
GLOBENEWSWIRE
Prometheus to Present at the SVB Securities Global Biopharma Conference
09 Feb 2023 //
GLOBENEWSWIRE
Prometheus Biosciences Stake Boosted by Russell Investments Group Ltd.
03 Feb 2023 //
MARKETBEAT
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
GLOBENEWSWIRE
Prometheus Announces Pricing of Public Upsized $500 M
08 Dec 2022 //
GLOBENEWSWIRE
Phase 2 bowel disease data fire Prometheus` stock up 170%
08 Dec 2022 //
FIERCEBIOTECH
Prometheus Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies
07 Dec 2022 //
GLOBENEWSWIRE
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
07 Dec 2022 //
GLOBENEWSWIRE
Prometheus moves to raise cash hours after PhII data leads to stock surge
07 Dec 2022 //
ENDPTS
Prometheus Biosciences Reports 3Q 2022 Financial Results
09 Nov 2022 //
GLOBENEWSWIRE
Prometheus Biosciences to Participate at November Healthcare Conferences
01 Nov 2022 //
GLOBENEWSWIRE
Prometheus Biosciences Receives FDA Clearance of IND Application
03 Oct 2022 //
GLOBENEWSWIRE
Companies Like Prometheus Bio Are In A Position To Invest In Growth
08 Sep 2022 //
NASDAQ
Prometheus Biosciences to Participate at September Healthcare Conferences
31 Aug 2022 //
GLOBENEWSWIRE
Prometheus Biosciences Reports Q2 2022 Rusult and Highlights Recent
11 Aug 2022 //
GLOBENEWSWIRE
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 PII Study
18 Jul 2022 //
GLOBENEWSWIRE
Prometheus Biosciences to Host Virtual R&D Day for Analysts and Investors
18 Jul 2022 //
GLOBENEWSWIRE
Prometheus Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC PII Studies
08 Jun 2022 //
GLOBENEWSWIRE
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
26 May 2022 //
GLOBENEWSWIRE
Prometheus Biosciences Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Prometheus delivers shareholders decent 43% return over 1 year
05 May 2022 //
YAHOO FINANCE
Prometheus Bio Initiates Third Phase 2 Study of PRA023 for SSc-ILD
30 Mar 2022 //
GLOBENEWSWIRE
Prometheus Bio Reports Q4 and FY 2021 Financial Results
09 Mar 2022 //
GLOBENEWSWIRE
Prometheus Bio to Participate at the Cowen 42nd Annual Healthcare Conference
01 Mar 2022 //
GLOBENEWSWIRE
Prometheus Biosciences to Participate at 11th Annual SVB Leerink Conference
07 Feb 2022 //
GLOBENEWSWIRE
Prometheus Bio Provides Corporate Updates at 40th JPM Conference
12 Jan 2022 //
GLOBENEWSWIRE
Prometheus Bio, Dr. Falk Pharma Advance PR600 and Trigger Milestone Payment
03 Jan 2022 //
GLOBENEWSWIRE
Prometheus Reports Positive Topline Ph1 Data Lead Therapeutic Candidate PRA023
07 Dec 2021 //
GLOBENEWSWIRE
Prometheus Reports Q3 2021 Financial Results and Highlights Corporate Progress
12 Nov 2021 //
GLOBENEWSWIRE
Abveris Announces Collaboration with Prometheus Biosciences
11 Nov 2021 //
PRNEWSWIRE
Prometheus to Present at Jefferies Virtual Next Gen IBD Therapeutics Summit
12 Oct 2021 //
GLOBENEWSWIRE
Scientific Innovator, Advisor & Board Chair Dr. Tadataka Yamada Has Passed Away
05 Aug 2021 //
GLOBENEWSWIRE
Prometheus Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023
02 Aug 2021 //
GLOBENEWSWIRE
Prometheus Announces Initiation of Global Phase 2 Clinical Trial of PRA023
19 Jul 2021 //
BIOSPACE
Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
15 Jul 2021 //
GLOBE NEWSWIRE
Prometheus Achieves Milestone Payment from Dr. Falk Pharma GmbH
21 Jun 2021 //
GLOBENEWSWIRE
Phase 1 biotech Prometheus Biosciences sets terms for $125 million IPO
08 Mar 2021 //
RENAISSANCE CAPITAL
Prometheus Announces Appointment of Mark Stenhouse as Chief Operating Officer
04 Mar 2021 //
PRNEWSWIRE
Prometheus Announces FDA Acceptance of IND Application for PRA023
15 Dec 2020 //
PRESS RELEASE
Prometheus Bio is ready for its close-up shot, following a $130M
09 Nov 2020 //
ENDPTS
Prometheus Biosciences Appoints Joseph C. Papa to its Board of Directors
24 Aug 2020 //
PRNEWSWIRE
Prometheus Biosciences and Dr. Falk Pharma Announce Collaboration Agreement
12 Aug 2020 //
PRNEWSWIRE
Prometheus Biosciences Appoints Keith W. Marshall as Chief Financial Officer
04 Aug 2020 //
PRNEWSWIRE
Prometheus Biosciences Launches Monitr™ COVID-19 Assistance Program (M.C.A.P.)
23 Mar 2020 //
PR NEWSWIRE
Prometheus Biosciences Inc. collaborates with Takeda for Multi-Target Strategic
04 Oct 2019 //
PR NEWSWIRE
